<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;L01C&quot;,&quot;href&quot;:&quot;atc/L01C.md&quot;},{&quot;label&quot;:&quot;vincristine&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Vincristine_Centanni2024_reference&quot;,&quot;label&quot;:&quot;Centanni_2024_reference&quot;,&quot;href&quot;:&quot;drugs/drug_vincristine/Vincristine_Centanni2024_reference.md&quot;,&quot;status&quot;:&quot;built, not shipped&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Vincristine_Igarashi2021_mean&quot;,&quot;label&quot;:&quot;Igarashi_2021_mean&quot;,&quot;href&quot;:&quot;drugs/drug_vincristine/Vincristine_Igarashi2021_mean.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Vincristine_Igarashi2021_standard_error_of_the_mean&quot;,&quot;label&quot;:&quot;Igarashi_2021_standard_error_of_the_mean&quot;,&quot;href&quot;:&quot;drugs/drug_vincristine/Vincristine_Igarashi2021_standard_error_of_the_mean.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false}]"></div>

# vincristine

- **generic name:** vincristine
- **ATC codes:** `L01CA02`
- **DrugBank:** [DB00541](https://go.drugbank.com/drugs/DB00541) · **PubChem:** [CID 5978](https://pubchem.ncbi.nlm.nih.gov/compound/5978)
- **molar mass:** 824.972 g/mol (C46H56N4O10) — DrugBank
- **groups:** approved, investigational

## About

**Description.** Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

**Indication.** Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 23:02 | 15:43 | 1/2/0 | 0/0/1 | 1/0/10 | 261,808/26,879 | ollama / qwen3.8:27b-mtp-q8_0 | 13 | 2/9 | 10/3 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">built, not shipped</span><br><sub>blocking: model_quarantined: Cl, Vd, k12, k21 left at base-class defaults</sub><br><sub>route_to: `scholar`</sub> | [Centanni_2024_reference](drugs/drug_vincristine/Vincristine_Centanni2024_reference.md) | held back | 2-compartment, IV | 5 | Centanni (2024) | — |
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: no distribution volume and no clearance/elimination — not a compartmental popPK…</sub><br><sub>route_to: `human_review`</sub> | [Igarashi_2021_mean](drugs/drug_vincristine/Vincristine_Igarashi2021_mean.md) | — | 1-compartment (no model) | 1 | Igarashi T et al., Population pharmacokinetic model develo…, Cancer chemotherapy and pha… (2021) | [10.1007/s00280-020-04220-y](https://doi.org/10.1007/s00280-020-04220-y) |
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: no structural parameters extracted (nothing to build)</sub><br><sub>route_to: `human_review`</sub> | [Igarashi_2021_standard_error_of_the_mean](drugs/drug_vincristine/Vincristine_Igarashi2021_standard_error_of_the_mean.md) | — | 1-compartment (no model) | 0 | Igarashi T et al., Population pharmacokinetic model develo…, Cancer chemotherapy and pha… (2021) | [10.1007/s00280-020-04220-y](https://doi.org/10.1007/s00280-020-04220-y) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> | [Centanni_2024_VIPN](drugs/drug_vincristine/pd_Centanni_2024_VIPN.md) | Vincristine-induced peripheral neuropathy (VIPN) ← vincristine · categorical (graded) response model | — | Centanni (2024) | — |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> | **MTNR1B** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [van_2022](drugs/drug_vincristine/pgx_van_2022_MTNR1B_safety.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **CEP72** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Christofyllakis_2024](drugs/drug_vincristine/pgx_Christofyllakis_2024_CEP72_Q100.md) | Christofyllakis K et al., An inherited genetic variant of the CEP…, Annals of hematology (2024) | [10.1007/s00277-024-05973-9](https://doi.org/10.1007/s00277-024-05973-9) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **CEP72** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [van_2022](drugs/drug_vincristine/pgx_van_2022_CEP72_Q100.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **ETAA1** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [van_2022](drugs/drug_vincristine/pgx_van_2022_ETAA1_Q100.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **FGD4** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [van_2022](drugs/drug_vincristine/pgx_van_2022_FGD4_Q100.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **FIG4** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [van_2022](drugs/drug_vincristine/pgx_van_2022_FIG4_Q100.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **GARS** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [van_2022](drugs/drug_vincristine/pgx_van_2022_GARS_Q100.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **NDRG1** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [van_2022](drugs/drug_vincristine/pgx_van_2022_NDRG1_Q100.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **RAB7A** | `Q88` · AUC | unknown | [van_2022](drugs/drug_vincristine/pgx_van_2022_RAB7A_Q88.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **SEPTIN9** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [van_2022](drugs/drug_vincristine/pgx_van_2022_SEPTIN9_Q100.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |
| <span class="pk-badge pk-badge--neutral">evidence_only</span> | **SNU13** | `Q88` · AUC | unknown | [van_2022](drugs/drug_vincristine/pgx_van_2022_SNU13_Q88.md) | van de Velde ME et al., Genetic Polymorphisms Associated with V…, Cancers (2022) | [10.3390/cancers14143510](https://doi.org/10.3390/cancers14143510) |

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=vincristine) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` inducer/inhibitor/substrate, `ABCG2` substrate | DrugBank actor |
| absorption | kidney | `ABCB1` inducer/inhibitor/substrate | DrugBank actor |
| absorption | liver | `ABCB1` inducer/inhibitor/substrate, `ABCG2` substrate | DrugBank actor |
| absorption | mammary gland | `ABCG2` substrate | DrugBank actor |
| absorption | placenta | `ABCB1` inducer/inhibitor/substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` inducer/inhibitor/substrate, `ABCG2` substrate | DrugBank actor |
| absorption | testis | `ABCB1` inducer/inhibitor/substrate, `ABCG2` substrate | DrugBank actor |
| distribution | blood-brain barrier | `ABCC1` inhibitor/substrate | DrugBank actor |
| distribution | liver | `SLC22A3` inhibitor | DrugBank actor |
| distribution | lung | `ABCC1` inhibitor/substrate | DrugBank actor |
| distribution | placenta | `SLC22A3` inhibitor | DrugBank actor |
| distribution | skeletal muscle | `SLC22A3` inhibitor | DrugBank actor |
| metabolism | kidney | `CYP3A5` substrate | DrugBank actor |
| metabolism | liver | `CYP3A4` substrate, `CYP3A5` substrate, `CYP3A7` substrate, `SLCO1B1` inhibitor, `SLCO1B3` inhibitor | DrugBank actor |
| metabolism | small intestine | `CYP3A4` substrate, `CYP3A5` substrate | DrugBank actor |
| excretion | bile duct | <sub>“…of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via…”</sub> | prose |
| excretion | kidney | `ABCC2` inhibitor/substrate | DrugBank actor |
| excretion | liver | `ABCB11` substrate, `ABCC2` inhibitor/substrate, `ABCC3` inhibitor | DrugBank actor |
| excretion | small intestine | `ABCC2` inhibitor/substrate, `ABCC3` inhibitor | DrugBank actor |

<sub>Actors without a tissue in the table: ABCC10 (inhibitor), ABCC10 (substrate), CEP72 (target), ETAA1 (target), FGD4 (target), FIG4 (target), GARS (target), MTNR1B (safety_allele), NDRG1 (target), RAB7A (unknown), RALBP1 (substrate), SEPTIN9 (target), SNU13 (unknown), TUBA4A (inhibitor), TUBB (inhibitor).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 584 matched, 73 returned
- **screened:** 3  ·  **relevant:** 3
- **records:** 3  ·  extracted 0  ·  needs_review 1  ·  rejected 2  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_3 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Barnett_2022.pdf` | Barnett S et al., Vincristine dosing, drug exposure and t…, European journal of cancer… (2022) | popPK | 10 | [10.1016/j.ejca.2021.09.014](https://doi.org/10.1016/j.ejca.2021.09.014) | [34657763](https://pubmed.ncbi.nlm.nih.gov/34657763) | The paper describes a population PK model for vincristine, but the specific numeric parameter values (CL, V, Q) are not present in the provided evidence, likely residing in tables or supplementary material not included. |
| `Owellen_1977.pdf` | Owellen RJ et al., Pharmacokinetics of vindesine and vincr…, Cancer research (1977) | popPK | 10 | not captured | [872088](https://pubmed.ncbi.nlm.nih.gov/872088) | The paper reports quantitative compartmental pharmacokinetic parameters (half-lives and volumes) for vincristine in humans directly in the text. |
| `Yuan_2025.pdf` | Yuan Y et al., Pharmacokinetic, Pharmacodynamic and Ph…, Clinical pharmacology and t… (2025) | popPK | 10 | [10.1002/cpt.3462](https://doi.org/10.1002/cpt.3462) | [39367622](https://pubmed.ncbi.nlm.nih.gov/39367622) | The paper describes a population pharmacokinetic study for vincristine, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |

<sub>queue written 2026-09-15T22:48:10.644837+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Barnett_2022 | relevant | 10 | 2 | The paper describes a population PK model for vincristine, but the specific numeric parameter values (CL, V, Q) are not present in the provided evidence, likely residing in tables or supplementary material not included. |
| PGx | Beraldo-Neto_2024 | not_relevant | 0 | 0 | The study analyzes proteomic mechanisms of multidrug resistance in a cell line and does not report pharmacogenomic effects on PK or PD parameters in humans. |
| popPK | Casanova_2023 | irrelevant | 1 | 0 | The study focuses on the pharmacokinetics of regorafenib and irinotecan, with vincristine serving only as a co-administered comparator agent without reported PK parameters. |
| PGx | Centanni_2024 | not_relevant | 0 | 0 | The paper investigates PK/PD modeling and MIPD for vincristine but does not report a specific pharmacogenomic effect (e.g., CYP3A5 genotype) on PK or PD parameters; CYP3A5 is only mentioned as a population distribution for simulation. |
| PGx | Cheon_2017 | not_relevant | 0 | 0 | The paper investigates the effect of JAK2 inhibitors on P-gp mediated resistance to vincristine in cancer cell lines, not the effect of a human gene variant on vincristine pharmacokinetics or pharmacodynamics. |
| PGx | Chieli_2009 | not_relevant | 0 | 0 | The study investigates the effect of plant compounds on P-gp activity in vitro, not the effect of a genetic variant on vincristine pharmacokinetics or pharmacodynamics. |
| popPK | Chopra_2016 | irrelevant | 0 | 0 | The paper is an in-vitro mechanistic study of a novel compound (AK301) where vincristine is used only as a comparator agent, and no pharmacokinetic parameters are reported. |
| PD | Chopra_2016 | not_relevant | 0 | 0 | The paper focuses on the mechanism of action of AK301 and compares it to vincristine using fixed concentrations (e.g., 500 nM) without reporting a dose-response curve or numeric PD parameters for vincristine. |
| popPK | Clarion_2012 | irrelevant | 0 | 0 | The paper is a medicinal chemistry study on new compounds for glioblastoma, and vincristine is only mentioned as a comparator for toxicity, with no pharmacokinetic data reported. |
| PD | Clarion_2012 | not_relevant | 0 | 0 | The paper focuses on the synthesis and in vitro screening of new oxaphosphinane compounds, mentioning vincristine only as a qualitative comparator for toxicity and potency without providing any exposure-response or dose-response data for vincristine. |
| PGx | Deshpande_2016 | not_relevant | 0 | 0 | The paper investigates the pharmacodynamic effect of the ABCB1 mutation on acepromazine, not vincristine. |
| PGx | Fleming_2026 | not_relevant | 0 | 0 | The paper investigates mechanisms of chemotherapy resistance in Wilms tumor (epigenetic changes, ABCB1 upregulation) but does not report pharmacogenomic effects of specific gene variants on vincristine PK or PD parameters. |
| PGx | Hofman_2021 | not_relevant | 0 | 0 | The study explicitly states that the pharmacological activity of vincristine was not influenced by CYP3A4 or CYP3A5 overexpression, reporting a negative result for the drug in question. |
| PD | Igarashi_2021 | not_relevant | 0 | 0 | The text only reports pharmacokinetic (PK) variability parameters (IIV, residual error) for a population PK model and contains no pharmacodynamic (PD) or exposure-response data. |
| popPK | Knoerl_2025 | irrelevant | 0 | 0 | The study investigates the association between CEP72 genotype and chemotherapy-induced peripheral neuropathy severity, reporting no pharmacokinetic parameters for vincristine. |
| PGx | Kwan_2024 | not_relevant | 0 | 0 | The paper discusses pharmacogenomics of mercaptopurine (6MP) and methotrexate, not vincristine. |
| popPK | Levêque_1996 | irrelevant | 0 | 0 | The paper is a review of the pharmacokinetics of vinorelbine, not vincristine, which is only mentioned as a mechanistic comparator. |
| PGx | Lewis_2017 | not_relevant | 0 | 0 | The paper reports that ABCG2 variants do not confer resistance to vincristine, indicating no effect on its pharmacodynamic parameter. |
| popPK | Liu_2022 | irrelevant | 0 | 0 | The study focuses on rituximab pharmacokinetics and exposure-response, with vincristine only listed as a component of the R-CHOP regimen without any PK parameters reported for it. |
| PD | Liu_2022 | not_relevant | 0 | 0 | The paper analyzes the exposure-response relationship for rituximab, not vincristine. |
| PGx | Marques_2021 | not_relevant | 0 | 0 | The paper investigates the effect of quercetin on MDR cells and vincristine efficacy, but does not report pharmacogenomic effects of genetic variants on vincristine PK or PD parameters. |
| PGx | Mealey_2015 | not_relevant | 0 | 0 | The paper is a review of P-glycoprotein-mediated drug-drug interactions in veterinary medicine and does not report pharmacogenomic effects on vincristine PK/PD parameters. |
| popPK | Mehrdadi_2024 | irrelevant | 0 | 0 | The study is a longitudinal evaluation of taste changes in pediatric oncology patients and does not report any pharmacokinetic parameters for vincristine. |
| PGx | Michaelis_2016 | not_relevant | 0 | 0 | The paper investigates the effect of pirinixic acid derivatives on ABCB1-mediated transport of vincristine, not the effect of a gene variant/genotype on vincristine pharmacokinetics or pharmacodynamics. |
| PGx | Mortensen_2024 | not_relevant | 0 | 0 | The paper investigates the mechanism of neurotoxicity and drug transport in a cell model but does not report pharmacogenomic effects (gene variants) on PK or PD parameters in humans. |
| PGx | Mufti_2024 | not_relevant | 0 | 0 | The study reports genetic associations with the risk of a clinical adverse event (peripheral neuropathy), not changes in pharmacokinetic or pharmacodynamic parameters. |
| PGx | Nakayama_2024 | not_relevant | 0 | 0 | The study examines drug sensitivity in cell lines with altered ABCB1 expression due to everolimus resistance, not a human genetic variant (pharmacogenomics) affecting vincristine PK/PD. |
| popPK | Olszewska-Słonina_2004 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of apoptosis and cell cycle effects, reporting no pharmacokinetic parameters such as clearance or volume of distribution. |
| PGx | Rossi_2017 | not_relevant | 0 | 0 | The paper focuses on tumor genotyping and clonal evolution in DLBCL using liquid biopsy, not on host pharmacogenomics affecting vincristine PK/PD. |
| popPK | Rosson_2002 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic/cytotoxicity assessment reporting EC50 values, not a pharmacokinetic study with disposition parameters. |
| popPK | Roundhill_2019 | irrelevant | 0 | 0 | The paper is a mechanistic study on drug resistance in osteosarcoma cells and does not report pharmacokinetic parameters for vincristine. |
| PD | Roundhill_2019 | not_relevant | 1 | 0 | The paper discusses drug resistance mechanisms in osteosarcoma cells and mentions vincristine resistance qualitatively, but it does not report any exposure-response or dose-response analysis with numeric PD parameters for vincristine. |
| PGx | Sabnis_2019 | not_relevant | 2 | 5 | The paper reports that ABCB1 expression (a phenotype/protein level, not a specific germline gene variant/genotype) correlates with drug resistance and survival, but it does not report a pharmacogenomic effect of a specific genetic variant on a PK or PD parameter of vincristine. |
| popPK | Samineni_2022 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of venetoclax, with vincristine serving only as a component of the R-CHOP combination therapy without any reported PK parameters. |
| PD | Samineni_2022 | not_relevant | 0 | 0 | The paper reports exposure-response analyses for venetoclax, not vincristine; no PD parameters for vincristine are provided. |
| PGx | Toksvang_2022 | not_relevant | 0 | 0 | The paper focuses on the pharmacogenomics of methotrexate and 6-mercaptopurine (TPMT/NUDT15) and does not report any gene variants affecting the pharmacokinetics or pharmacodynamics of vincristine. |
| popPK | Toso_1995 | irrelevant | 0 | 0 | The paper is a review of vinorelbine, not vincristine, and does not report quantitative PK parameters for vincristine. |
| PGx | Yeung_2025 | not_relevant | 0 | 0 | The paper investigates the neurotoxic effects of vincristine in Sarm1 knockout mice, focusing on brain volume and axon morphology, but does not report pharmacokinetic or pharmacodynamic parameters of the drug itself. |
| popPK | Yuan_2025 | relevant | 10 | 0 | The paper describes a population pharmacokinetic study for vincristine, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |
| PGx | Zhou-Pan_1993 | not_relevant | 0 | 0 | The paper investigates vinblastine metabolism and CYP3A4 involvement, not vincristine pharmacogenomics. |
| popPK | van_2022 | relevant | 8 | 2 | The study reports vincristine PK parameters (AUC, Cmax) and uses a two-compartment model, but specific clearance, volume, or half-life values are not explicitly listed in the provided text, only summary statistics and references to figures/tables. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-15 22:50 UTC</sub>
